强生公司周四表示由于一项中期试验的结果没有显示出足够的疗效该公司决定不再继续开发针对一种关节炎患者的联合用药。该公司正在研究将其药物尼泊卡利单抗与一种抗肿瘤坏死因子α治疗相结合后者有助于阻止炎症。在中期试验中对于难以治疗的类风湿性关节炎患者联合疗法未能显示出比单独使用抗肿瘤坏死因子α疗法更显著的疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.